McKesson (MCK) Scheduled to Post Earnings on Wednesday

McKesson (NYSE:MCK) is set to post its earnings results after the market closes on Wednesday, November 6th. Analysts expect McKesson to post earnings of $7.09 per share for the quarter. McKesson has set its FY25 guidance at $31.75-32.55 EPS and its FY 2025 guidance at 31.750-32.550 EPS.Investors that wish to register for the company’s conference call can do so using this link.

McKesson (NYSE:MCK) last announced its earnings results on Wednesday, August 7th. The company reported $7.88 EPS for the quarter, beating the consensus estimate of $7.21 by $0.67. The business had revenue of $79.28 billion for the quarter, compared to the consensus estimate of $82.53 billion. McKesson had a negative return on equity of 242.57% and a net margin of 0.94%. The company’s revenue was up 6.4% on a year-over-year basis. During the same period last year, the business posted $7.27 EPS. On average, analysts expect McKesson to post $32 EPS for the current fiscal year and $35 EPS for the next fiscal year.

McKesson Stock Down 0.1 %

NYSE MCK opened at $525.94 on Tuesday. The stock has a market cap of $68.20 billion, a PE ratio of 23.52, a P/E/G ratio of 1.17 and a beta of 0.44. The business has a 50 day moving average price of $511.62 and a two-hundred day moving average price of $550.62. McKesson has a fifty-two week low of $431.35 and a fifty-two week high of $637.51.

McKesson Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, January 2nd. Stockholders of record on Monday, December 2nd will be paid a $0.71 dividend. The ex-dividend date is Monday, December 2nd. This represents a $2.84 annualized dividend and a dividend yield of 0.54%. McKesson’s dividend payout ratio (DPR) is presently 12.70%.

Insider Buying and Selling at McKesson

In related news, CEO Brian S. Tyler sold 3,753 shares of the stock in a transaction dated Thursday, September 5th. The shares were sold at an average price of $561.10, for a total transaction of $2,105,808.30. Following the sale, the chief executive officer now owns 78,586 shares in the company, valued at $44,094,604.60. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.11% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

A number of brokerages have commented on MCK. Barclays boosted their price objective on shares of McKesson from $596.00 to $616.00 and gave the stock an “overweight” rating in a report on Thursday, August 8th. StockNews.com cut McKesson from a “buy” rating to a “hold” rating in a research note on Friday, September 27th. Evercore ISI lowered their price objective on McKesson from $660.00 to $630.00 and set an “outperform” rating for the company in a research note on Thursday, August 8th. Wells Fargo & Company cut their target price on McKesson from $576.00 to $535.00 and set an “equal weight” rating on the stock in a research report on Friday, September 13th. Finally, Citigroup reduced their target price on McKesson from $670.00 to $630.00 and set a “buy” rating for the company in a research note on Tuesday, September 10th. Five research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $610.86.

McKesson Company Profile

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products.